New York, January 21, 2026, 12:40 EST — Regular session
- AbbVie shares up about 0.4% at $214.92 in midday trade
- Berenberg raised its target to $275; Bernstein kept a Hold with a $225 target
- Investors are watching U.S. pharma tariff headlines and AbbVie’s Feb. 4 results
AbbVie Inc shares were up 88 cents, or about 0.4%, at $214.92 in midday trading on Wednesday, a muted move after a fresh round of analyst target changes. The stock has traded between $211.92 and $218.00, with about 5.3 million shares changing hands.
It matters now because drugmakers are heading into results season with policy risk back in the tape. AbbVie’s setup is familiar: investors want proof that newer brands can keep carrying growth while the company navigates tighter pricing.
Washington is also back in the conversation. The Trump administration is considering a 100% tariff on imported branded and patented medicines, and drugmakers have been accelerating U.S. manufacturing plans and inventory moves as they try to blunt any hit. AbbVie has said it is “fairly insulated” from tariff impact this year given inventory actions, and Reuters reported the company has committed $100 billion over the next decade to U.S.-based research and development as part of a three-year deal tied to reducing drug prices. Reuters
Berenberg raised its price target on AbbVie to $275 from $270 and kept a buy rating, citing what it called an “exceptional” growth outlook for AbbVie’s Skyrizi and Rinvoq. Price targets are analysts’ estimates of where a stock could trade over the next 12 months. TipRanks
Berenberg analyst Luisa Hector’s target lift came a day after Bernstein’s Courtney Breen kept a hold rating and raised her target price to $225 from $203, TipRanks data showed.
The broader tone in health care was firmer. The Health Care Select Sector SPDR Fund was up about 1.1%, outpacing the SPDR S&P 500 ETF, which was up about 0.4%. Johnson & Johnson was down nearly 1% after a busy morning of headlines, while Eli Lilly shares were up close to 3%.
Johnson & Johnson, one of AbbVie’s large-cap peers, forecast 2026 profit above Wall Street estimates despite the expected impact of a drug pricing deal with the Trump administration and tariffs exposure. Chief Financial Officer Joseph Wolk said the pricing deal would cost it “hundreds of millions of dollars.” Reuters
For AbbVie, investors still tend to anchor on the pace of its pivot away from Humira, once its best-selling arthritis treatment, and toward Skyrizi and Rinvoq. The company has said it is leaning on those newer immunology drugs to offset declining U.S. Humira sales after close copies entered the market.
But the downside case has not gone away. Competition in immunology is tightening, and policy pressure on drug pricing can hit sentiment quickly even when the direct financial impact is harder to pin down. Any wobble in demand trends or an unexpected regulatory snag can also move the story in a hurry.
The next clear catalyst is AbbVie’s full-year and fourth-quarter 2025 report on Feb. 4, due before the market opens, with a conference call scheduled for 8 a.m. Central time.
